Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 4/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.30 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13545483 | 1.00 | CRBN (0.34) | CRBNCA9TRPV1NR1H2DRD2 | |
| SCHEMBL13545486 | 0.84 | CRBN (0.38) | CRBNCA9TRPV1DRD2DRD4 | |
| SCHEMBL13545484 | 0.84 | FKBP1A (0.35) | CRBNCA9TRPV1NR1H2DRD2 | |
| SCHEMBL3596516 | 0.80 | ALOX15 (0.33) | CRBNCA9DDB1IKZF3 | |
| SCHEMBL3595503 | 0.80 | CA9 (0.39) | CRBNCA9TRPV1DRD2DRD4 | |
| SCHEMBL3596750 | 0.78 | CRBN (0.41) | CRBNCA9TRPV1DRD2DRD4 | |
| SCHEMBL13545482 | 0.78 | CRBN (0.41) | CRBNCA9TRPV1DRD2DRD4 | |
| SCHEMBL3602519 | 0.77 | CRBN (0.40) | CRBNCA9TRPV1DRD2DRD4 | |
| SCHEMBL13545485 | 0.76 | CRBN (0.37) | CRBNCA9TRPV1DRD2DRD4 | |
| SCHEMBL3605706 | 0.76 | PARP1 (0.32) | CRBNCA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128157-A1 | HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | CCNY, CCND3, NSD3 | CRBN 762/4885CA9 1531/4885TRPV1 2518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.